Impact of Aldosterone on Vascular Pathophysiology
Open Access
- 1 January 2002
- journal article
- review article
- Published by Wiley in Congestive Heart Failure
- Vol. 8 (1) , 18-22
- https://doi.org/10.1111/j.1527-5299.2002.00722.x
Abstract
The fact that spironolactone reduces deaths in cardiac failure suggests that aldosterone promotes cardiac death in heart failure, which begs the question: What are the mechanisms whereby it does this? The mechanisms whereby aldosterone promotes cardiac death are likely to be a combination of its production of endothelial dysfunction, myocardial fibrosis, and autonomic imbalance. It is quite possible that all three of these mechanisms actually stem from aldosterone's adverse effects on the endothelium. The term “aldosterone vasculopathy” has been coined to describe that the fundamentally adverse effect of aldosterone may well be on endothelial nitric oxide.Keywords
This publication has 10 references indexed in Scilit:
- Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart FailureCirculation, 2000
- Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 ProductionJournal of Clinical Endocrinology & Metabolism, 2000
- Role of nitric oxide in the regulation of cardiovascular autonomic controlClinical Science, 1999
- Role of nitric oxide in the regulation of cardiovascular autonomic controlClinical Science, 1999
- Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients.Published by Oxford University Press (OUP) ,1998
- Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive RatsHypertension, 1998
- Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patientsCardiovascular Research, 1997
- Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropinJournal of Clinical Endocrinology & Metabolism, 1996
- Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 βEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.Circulation, 1991